Myelodysplastic Syndrome (MDS) Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),

Myelodysplastic Syndrome (MDS) Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

In myelodysplastic syndrome (MDS), some of the cells from bone marrow are abnormal and have problems making new blood cells. Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Moreover, awareness about the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.
Market Dynamics
Increasing prevalence of MDS is expected to increase the demand of such drugs, thereby expected to drive myelodysplastic syndrome treatment market growth over the forecast period. For instance, according to the 2015 report of American Cancer Society (ACS), the incidence rate for myelodysplastic syndrome was 13,000 new cases in the U.S. each year that occurs at a rate of 4.8 cases per 100,000 people.
Moreover, according to the 2015 report of American Cancer Society (ACS), incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. Moreover, the fact report of 2014-2015 published by Leukemia and Lymphoma Society suggests that the overall incidence of MDS in the U.S. by gender are 6.7 per 100,000 in male while 3.8 per 100,000 in females.
Key features of the study:
This report provides in-depth analysis of the global myelodysplastic syndrome treatment market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global myelodysplastic syndrome treatment market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansions, and marketing tactics
The global myelodysplastic syndrome treatment market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global myelodysplastic syndrome treatment industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Myelodysplastic Syndrome Treatment Market, By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
Global Myelodysplastic Syndrome Treatment Market, By Route Of Administration:
Injection
Oral
Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Myelodysplastic Syndrome Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug:
Lenalidomide
Decitabine
Azacitidine
Phase 3 Drugs
By Route of Administration:
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Celgene Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Otsuka Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited
Dr. Reddy's Laboratories Ltd.
Mylan NV
Cipla Limited
Acceleron Pharma, Inc.
Aprea Therapeutics
FibroGen Inc.
Onconova Therapeutics Inc.
Geron
“*” marked represents similar segmentation in other categories in the respective section